In 2023, a Phase I trial of ALLO-715, a TALEN-edited CAR-T product targeting BCMA for relapsed/refractory multiple myeloma (R/R MM), showed an overall response rate (ORR) of 55.8% among 43 patients. Here, TNFRSF17 is linked to plasma cell myeloma.